As at May 3, 2024, the JAZZ stock has a price-to-earnings ratio of 21.03. This is based on the current EPS of $5.23 and the stock price of $110.01 per share.
The mean historical PE ratio of Jazz Pharmaceuticals over the last ten years is 46.81. The current 21.03 P/E ratio is 55% lower than the historical average. In the past ten years, JAZZ's PE ratio peaked in the Sep 2014 quarter at 302.94, with a price of $160.56 and an EPS of $0.53. The Sep 2019 quarter marked the lowest point at 12.11, with a price of $128.14 and an EPS of $10.58.
Maximum annual increase: 389.8% in 2014
Maximum annual decrease: -84.36% in 2015
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 18.78 | N/A |
| 2022 | N/A | N/A |
| 2021 | N/A | N/A |
| 2020 | 38.56 | 138.17% |
| 2019 | 16.19 | -2.7% |
| 2018 | 16.64 | 0.48% |
| 2017 | 16.56 | -0.36% |
| 2016 | 16.62 | -36.39% |
| 2015 | 26.13 | -84.36% |
| 2014 | 167.07 | 389.8% |
The current PE ratio of JAZZ is lower than the 5 and 10-year averages.
In comparison to its peer stock NVS, JAZZ's PE ratio is higher.
| Stock name | PE ratio | Market cap |
|---|---|---|
| NVS Novartis AG | 13.17 | $199.13B |
| JAZZ Jazz Pharmaceuticals plc | 21.03 | $6.93B |
| TEVA Teva Pharmaceutical Industries Ltd | N/A | $15.8B |
| PRGO PERRIGO Co plc | N/A | $4.51B |
| SAGE Sage Therapeutics Inc | N/A | $811.25M |
The price to earnings ratio for JAZZ stock as of May 3, 2024, stands at 21.03.
The 5-year average price to earnings ratio for JAZZ stock is 43.15.
In the last ten years, the Sep 2014 quarter recorded the highest quarterly PE ratio at 302.94.
JAZZ's current price to earnings ratio is 55% below its 10-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (May 3, 2024), Jazz Pharmaceuticals's stock price is $110.01. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $5.23. Therefore, Jazz Pharmaceuticals's PE ratio for today is 21.03. PE RATIO(21.03) = STOCK PRICE($110.01) / TTM EPS($5.23)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.